ACRO Provides Comments on 21st Century CuresJuly 7, 2014 11:30 pm
Contact: John Lewis
Focus on EHRs, Tax Incentives, FDA Innovation
July 8, 2014 – Washington, D.C. – The Association of Clinical Research Organizations (ACRO) has provided the House Energy & Commerce Committee with its first set of recommendations for streamlining the drug development process.
ACRO’s recommendations focus on three themes:
- Encouraging the use of “big data” for research purposes and linking clinicaltrials.gov to electronic health record systems (EHRs) to raise awareness about clinical trials and promote patient recruitment;
- Expanding, simplifying and making permanent the Research & Development tax credit, including making a portion of the credit available for companies that conduct contract research;
- Ensuring that the Food and Drug Administration has adequate resources and fosters a culture that promotes innovation.
You may view ACRO’s full comments here.
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. The association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 100,000 professionals worldwide and annually conduct more than 11,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.